

Focus markets and exit strategy – Chordate CEO Anders Weilandt on Aktieportföljen live

At investor event Aktieportföljen Live, on October 15th, Chordate CEO Anders Weilandt talked about the appointment of Partner International Switzerland GmbH as an advisor to find a buyer for the business.

"If we focus on the exit, is it a partner (buyer) within the field of migraine or more of a medtech company or a distributor?"

"We are quite agnostic about who the best buyer could be. The easy answer is the one who pays the most, but it's somewhere in the area you're talking about. I would add besides the two obvious segments of the pharma industry and the medtech industry, a portfolio building structure that builds up product portfolio. It could very well be a company or outfit that we are unaware of. We do not really point our advisors in any specific direction. It's their job, which they are good at, to comb the market for people with the strategic thinking that see a reason to invest in this kind of very clear cut, specific technology, to add to a probably already existing portfolio", said Anders Weilandt till Aktieportföljen Live.

[View the presentation and Q&A in full](#)

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
16 October 2024 13:45:00 CEST

CHORDATE
M E D I C A L

Attachments

[Focus markets and exit strategy – Chordate CEO Anders Weilandt on Aktieportföljen live](#)